HNF1β is a sensitive and specific novel marker for yolk sac tumor: a tissue microarray analysis of 601 testicular germ cell tumors.
Adult
Biomarkers, Tumor
/ metabolism
Carcinoma, Embryonal
/ diagnosis
Choriocarcinoma
/ diagnosis
Diagnosis, Differential
Endodermal Sinus Tumor
/ diagnosis
Hepatocyte Nuclear Factor 1-beta
/ metabolism
Humans
Immunohistochemistry
Male
Seminoma
/ diagnosis
Sensitivity and Specificity
Teratoma
/ diagnosis
Testicular Neoplasms
/ diagnosis
Testis
/ metabolism
Tissue Array Analysis
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
13
05
2020
accepted:
05
06
2020
revised:
04
06
2020
pubmed:
21
6
2020
medline:
27
8
2021
entrez:
21
6
2020
Statut:
ppublish
Résumé
Hepatocyte Nuclear Factor 1 beta (HNF1β) is a transcription factor which plays an important role during early organogenesis, especially of the pancreato-biliary and urogenital tract. Furthermore, HNF1β is an established marker in the differential diagnosis of ovarian cancer and shows a distinct nuclear expression in the clear cell carcinoma subtype. Recently, it has been described in yolk sac tumor, which represents a common component in many non-seminomatous germ cell tumors. Due to its broad histologic diversity, the diagnosis may be challenging and additional tools are very helpful in the workup of germ cell tumors. Immunohistochemistry was used to study HNF1β expression in a tissue microarray (TMA) of 601 testicular germ cell tumors including seminoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma, germ cell neoplasia in situ (GCNIS), and normal tissue. The expression pattern was compared to glypican 3 (GPC3) and α-fetoprotein (AFP), two markers currently in use for the detection of yolk sac tumor. HNF1β showed a distinct nuclear staining in comparison to the cytoplasmic pattern of GPC3 and AFP. The sensitivity and specificity of HNF1β were 85.4% and 96.5%, of GPC3 83.3% and 90.7%, of AFP 62.5% and 97.7%. We conclude that HNF1β allows a reliable distinction of yolk sac tumor from other germ cell tumor components. Therefore, we propose HNF1β as a novel and robust marker in the immunohistochemical workup of testicular germ cell tumors.
Identifiants
pubmed: 32561848
doi: 10.1038/s41379-020-0597-x
pii: S0893-3952(22)00455-0
doi:
Substances chimiques
Biomarkers, Tumor
0
HNF1B protein, human
0
Hepatocyte Nuclear Factor 1-beta
138674-15-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2354-2360Références
Trabert B, Chen J, Devesa SS, Bray F, McGlynn KA. International patterns and trends in testicular cancer incidence, overall and by histologic subtype, 1973–2007. Andrology. 2015;3:4–12.
doi: 10.1111/andr.293
Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol. 2018;29:1658–86.
doi: 10.1093/annonc/mdy217
Ulbright TM, Amin MB, Balzer B, Berney DM, Epstein JI, Guo C, et al. Tumours of the testis and paratesticular tissue, In: Moch H, Humphrey PA, Ulbright TM, Reuter VE, editors. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon: WHO Press; 2016.
Rougemont A-L, Tille J-C. Role of HNF1β in the differential diagnosis from other germ cell tumors. Hum Pathol. 2018;81:26–36.
doi: 10.1016/j.humpath.2018.04.025
Bode PK, Barghorn A, Fritzsche FR, Riener MO, Kristiansen G, Knuth A, et al. MAGEC2 is a sensitive and novel marker for seminoma: a tissue microarray analysis of 325 testicular germ cell tumors. Mod Pathol. 2011;24:829.
doi: 10.1038/modpathol.2011.6
Ulbright TM, Tickoo SK, Berney DM, Srigley JR, Group IIiDUP. Best practices recommendations in the application of immunohistochemistry in testicular tumors: report from the International Society of Urological Pathology consensus conference. Am J Surg Pathol. 2014;38:e50–9.
doi: 10.1097/PAS.0000000000000233
Ulbright TM. Pitfalls in the interpretation of specimens from patients with testicular tumours, with an emphasis on variant morphologies. Pathology. 2018;50:88–99.
doi: 10.1016/j.pathol.2017.07.013
Rajab R, Berney DM. Ten testicular trapdoors. Histopathology. 2008;53:728–39.
doi: 10.1111/j.1365-2559.2008.03001.x
Kao C-S, Idrees MT, Young RH, Ulbright TM. Solid pattern yolk sac tumor: a morphologic and immunohistochemical study of 52 cases. Am J Surg Pathol. 2012;36:360–7.
doi: 10.1097/PAS.0b013e31823c510b
Nogales FF, Preda O, Nicolae A. Yolk sac tumours revisited. A review of their many faces and names. Histopathology. 2012;60:1023–33.
doi: 10.1111/j.1365-2559.2011.03889.x
Mizejewski GJ. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp Biol Med. 2001;226:377–408.
doi: 10.1177/153537020122600503
Gilligan TD, Seidenfeld J, Basch EM, Einhorn LH, Fancher T, Smith DC, et al. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol. 2010;28:3388–404.
doi: 10.1200/JCO.2009.26.4481
Tsuchida Y, Kaneko M, Fukui M, Sakaguchi H, Ishiguro T. Three different types of alpha-fetoprotein in the diagnosis of malignant solid tumors: use of a sensitive lectin-affinity immunoelectrophoresis. J Pediatr Surg. 1989;24:350–5.
doi: 10.1016/S0022-3468(89)80267-2
Zynger DL, Dimov ND, Luan C, Teh BT, Yang XJ. Glypican 3: a novel marker in testicular germ cell tumors. Am J Surg Pathol. 2006;30:1570–5.
doi: 10.1097/01.pas.0000213322.89670.48
Zynger DL, McCallum JC, Luan C, Chou PM, Yang XJ. Glypican 3 has a higher sensitivity than alpha-fetoprotein for testicular and ovarian yolk sac tumour: immunohistochemical investigation with analysis of histological growth patterns. Histopathology. 2010;56:750–7.
doi: 10.1111/j.1365-2559.2010.03553.x
Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005;18:1591–8.
doi: 10.1038/modpathol.3800436
Aviel-Ronen S, Lau SK, Pintilie M, Lau D, Liu N, Tsao MS, et al. Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol. 2008;21:817–25.
doi: 10.1038/modpathol.2008.37
Ou-Yang RJ, Hui P, Yang XJ, Zynger DL. Expression of glypican 3 in placental site trophoblastic tumor. Diagn Pathol. 2010;5:64.
doi: 10.1186/1746-1596-5-64
Umezu T, Shibata K, Kajiyama H, Yamamoto E, Nawa A, Kikkawa F. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary. J Clin Pathol. 2010;63:962–6.
doi: 10.1136/jcp.2010.080234
Bach I, Mattei M-G, Cereghini S, Yaniv M. Two members of an HNF1 homeoprotein family are expressed in human liver. Nucleic Acids Res. 1991;19:3553–9.
doi: 10.1093/nar/19.13.3553
Barbacci E, Reber M, Ott MO, Breillat C, Huetz F, Cereghini S. Variant hepatocyte nuclear factor 1 is required for visceral endoderm specification. Development. 1999;126:4795–805.
pubmed: 10518496
Coffinier C, Barra J, Babinet C, Yaniv M. Expression of the vHNF1/HNF1beta homeoprotein gene during mouse organogenesis. Mech Dev. 1999;89:211–3.
doi: 10.1016/S0925-4773(99)00221-X
El‐Khairi R, Vallier L. The role of hepatocyte nuclear factor 1β in disease and development. Diabetes, Obes Metab. 2016;18:23–32.
doi: 10.1111/dom.12715
Rebouissou S, Vasiliu V, Thomas C, Bellanné-Chantelot C, Bui H, Chrétien Y, et al. Germline hepatocyte nuclear factor 1α and 1β mutations in renal cell carcinomas. Hum Mol Genet. 2005;14:603–14.
doi: 10.1093/hmg/ddi057
Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet. 2008;40:310.
doi: 10.1038/ng.91
Kato N, Sasou S-i, Motoyama T. Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol. 2006;19:83.
doi: 10.1038/modpathol.3800492
Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol. 2003;163:2503–12.
doi: 10.1016/S0002-9440(10)63605-X
Fadare O, Zhao C, Khabele D, Parkash V, Quick CM, Gwin K, et al. Comparative analysis of Napsin A, alpha-methylacyl-coenzyme A racemase (AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma: an immunohistochemical study of 279 ovarian tumours. Pathology. 2015;47:105–11.
doi: 10.1097/PAT.0000000000000223
Nogales FF, Prat J, Schuldt M, Cruz-Viruel N1, Kaur B3, D’Angelo E, et al. Germ cell tumour growth patterns originating from clear cell carcinomas of the ovary and endometrium: a comparative immunohistochemical study favouring their origin from somatic stem cells. Histopathology. 2018;72:634–47.
doi: 10.1111/his.13426
Preda O, Nicolae A, Aneiros-Fernandez J, Borda A, Nogales FF. Glypican 3 is a sensitive, but not a specific, marker for the diagnosis of yolk sac tumours. Histopathology. 2011;58:312–4.
doi: 10.1111/j.1365-2559.2010.03735.x
Berney DM, Lu YJ, Shamash J, Idrees M. Postchemotherapy changes in testicular germ cell tumours: biology and morphology. Histopathology. 2017;70:26–39.
doi: 10.1111/his.13078
Howitt BE, Magers MJ, Rice KR, Cole CD, Ulbright TM. Many postchemotherapy sarcomatous tumors in patients with testicular germ cell tumors are sarcomatoid yolk sac tumors: a study of 33 cases. Am J Surg Pathol. 2015;39:251–9.
doi: 10.1097/PAS.0000000000000322
Sung MT, Jones TD, Beck SD, Foster RS, Cheng L. OCT4 is superior to CD30 in the diagnosis of metastatic embryonal carcinomas after chemotherapy. Hum Pathol. 2006;37:662–7.
doi: 10.1016/j.humpath.2006.01.019
O’Shaughnessy MJ, Feldman DR, Carver BS, Sheinfeld J. Late relapse of testicular germ cell tumors. Urol Clin North Am. 2015;42:359–68.
doi: 10.1016/j.ucl.2015.04.010